Supplier problems cost AFT Pharmaceuticals $A2m
Pharmaceuticals company is aiming for 60% of its revenue to be generated outside of Australia and New Zealand in five years' time. With special feature audio.
AFT Pharmaceuticals [NZX: AFT] says it lost approximately $A2 million in revenue due to low production levels from a significant supplier.
In its maiden full-year results since listing, the Auckland-based drug development company announced total revenue rose 14% to $64 million and an operating
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Smartphone Only Annual Subscription
NZ$249.00 / yearly
Monthly Premium Online Subscription
NZ$49.95 / monthly
Smartphone Only Subscription
NZ$29.95 / monthly
Premium Group Membership 10 Users
NZ$385+GST / monthly
$38.5 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$660+GST / monthly
$33 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1375+GST / monthly
$27.5 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$2100+GST / monthly
$21 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Campbell Gibson
Wed, 25 May 2016
Wed, 25 May 2016
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Supplier problems cost AFT Pharmaceuticals $A2m
58485